Risk factor analysis for stent occlusion within the first month after successful coronary stent placement  by Schömig, A. et al.
JACC February 1998 ,~BSTRA(.'~'S ~ Po,,t¢¢ ~tA 
randomized trials while a certain practice at vahanco with con¢lus~,ns from 
meanm~,e~ trials may I~ explained by more optimal conventional PTCA 
made possible by the stent option, 
St tnt  Uae In Internal Mammary  Graft Angloplasty 
- A 4 -YRr  Exper ien~ 
M, T~be~, M, Mimlo~, G, Plud~, R, M~hr~n, E, Pinnaw, S, ~l~ke~r, 
1", O~¢l~r, J. Popma, A. P~'~,d, J, Um~Ls~y, Jr. I/V~t~ngt~ H~/~f~t 
Cen~r. ~ ,  ~ USA 
routir~, in r~t  catt'~t~zat~n ~ent~r~, ~um~n~t J~ ~ eff~cy 
el st~t~ in IMA ~I t  ~t~ ~s  ~ been reported, 
M#/t I~:  IMA 9r~Jft OP ,~)~i~/~ p~oet11~ in 145 I~t~ t O~r it~tit~r~on 
between Ja~l~ly leg4 ~ M, W 1997, StifflY, ~m d~k~yed il~ ~ (19,~;~,), 
Of I~11~ M~I{~/ .  I~ l Jon  fg~ Ment I ~ t  W~S r~0l ~mnt  !n 
B I~l, L~mn Io¢~ti(m wltt~n the IMA w~ ~n in i t§  ply. Only 10 (36%) 
w~m ~ in an ~ site ~ ~ ~ ~teno~ ~'c~nled 
I~ ?'~'~ Of Oft tr~te¢l e~s .  Hm~p~r, mean age ~ lha ~ratl in the two 
P ~  w~s sm'~Tar I~te  and L~t~,n  o~t~ (6 month~ to 3 
years) m ~ pts ~ ehown be~k~w. No stem pt ~e~, ~ ~ut ,  mwcardia~ 
(nf~ct,~n Ot emer~nt CA~3 ~ tO the PmCt~m. The ;2 d~Wm m 
Merit ~ o¢~lmd within (;me ~ from t)~ l~x:e(k~re. Both had ~vere 
~oa~t  d~s~ase. One was in CardiogeniC ShOCk end ~ red~ GABG 
week I~tm. 
No-stenr 89 82 8 i o 275 4 (3.9%) 
Stem 24 964 7 4 i ~aS 2 (9.5%) 
Conct~ Slant use m IMA graft a ,~ las ty  in prol~dy self'ted pts is 
safe ar~ efficacious. 
• F~¢~.C~IUtal Results and Late Clinical Outcomes 
Fol lowing Mult ivessel  Coronary  Slentin 9 
R KOmowski, LF. Salter,/LD. Pichard, KM. KenL MK. l-kmo R. Mehran, 
JJ. Pot:~na, J.R Laird, M.B, Lemn. Washington Hospt~ Center, DC. JSA 
Back~m~,ed: Conventional PTCA m muttme, ssel coronary disease has been 
limited by higher rate el restenosis and recunent angina compared to single- 
vessel coronary interventions. 
Methods: We evaluated procedural success, major ln+hoSl:ntal compli- 
C~bons, repeat revascularization and ctin~c~l outcomes @ (1 ye~) in 2,377 
consecutive patients (3,552 nat~vecomnaty lesions) who underwent one-t/me 
procedure of multJvessal (94% with Iwo vessels stenfmg) vs. sir~Pvessel 
stenting. Repeat revasculafization is reporled @ 1 year per.patient and im 
dudes all target lesion and target veSsel revaScularizatlons for single and 
multiple vessel disease. 
Results: (Tatge) 
# ~essels (# Patients) S~ng/e (r958) MuJr~ (~rg) P 
Procedure success (%) 97 t 962 036 
Hospital death/Ml/CAJ~G (%) 0.610.7/I 6 05/O 9/05 0 31(0.65/0.08 
Repeat mva.scu~mza~on (%) 200 21 6 056 
Deatll~11 ( yr) (%) 1 5/1 3 07(0 020/002 
Event-free survival (1 yr) (%) 759 779 0.81 
Cot~clusions: Unlike previous PTCA experier~'es, mull~vesseI coronary 
startling does not confer incremental procedural complications or repeat 
revaSculahzation dsk compared with single vessel treatment. Thus, slant- 
ing may be the preferred therapeutic strategy in patients with multivessel 
coronary disease. 
~ R i s k  for  Procedural Fai lure at  Coronary Stent 
Placement 
H. SchQhlen, A. Kastrati, J. Hausieiter, S. Elezi, J. Dirschinger, A. $chbmig. 
DeutsChes Herzzentrum & Klinikum rechts der Isar, Technische UniversitdL 
Munich, Germany 
Background: The utilization of coronary stents has been growing continu- 
ously with broadening indications, Although stent placement is technically 
more difficult than stander~ PTCA, it may be achieved with high success 
rates, However, a comDml~ens=ve ~t'~lyst~,  tt~ n~ of IX¢~J~r~l t~e ~' 
assom~t~l aff~ePse ven~ is r~t eV~l~L~e, 
Me~Od~; W~ analyzed all ~B94 ~l~ntmg ~'o¢~'~u~ mtl~ k~t ~ ye-~r~ 
I~d0nlle~ at Our in~tit~to~ (~,l~',e ha~ted  ~(~t~ ~,1(~t'ff~) 
Re~.~/t~ Pr0¢~dural ~e,¢ce~ (l~tcem~nt al tMg64 ipo~tkott wtlh =30% 
myo~l  in f~t~ (MI), 14,8 vs, 2,0% (OR 1~,4~ Ct, 3,~=1tL3), ~1~,  MI 
t~ I~tt; t~  moet ~g~ir~nt t~o~ w~ tl~ i ~  ~ m ~r~ 
r~m~t  t~t~l~e~ t5 ~d~t io~ facto~ w~l  into me ~ w~ not 
~ed in ~c~ MI. 
~temottl~ grime -~-  
~lllnllng 
~1 1 10 
Con¢lu~on~: The rote of IprOcR~#-~ spCCeS~ iS high,/),tier f~dure I I~ ,  
undersc~e, ~ need lo~ ol~miza~on of techncal eq~t  as well em 
ot~mti~lal skifl~. 
• Comnsry 5~n~ng With Different Indic~Uons 
Y K~td ,  M. Far.re, B, Rmmers, T, AkqFama, J. de Gregorm, C. Di 
Made, G. M3rttni, L D( Francesca, L. Rnej, A. CO~ Centre C~om 
Columbus, M~tano, tta~ 
The I~tpose ol Ibis Study was to (teteml~ie medium-ffirm ~(n~l  ~ 8n- 
g,,ographic results m patients having ¢oronarf slant deployment for venous 
[lldicatig~ TI~ literature sllows dNer$~ results with different C l~ l  in, 
dicatLons. We analy~e~ t~s re.~tS Of Cor0r~ry Stent in'tptanlat~n for the 
following indications: elective therapy, for restenosis after at~JmplaSly (Rest), 
for a subop~mal result after angioplasty (Sul~opt R), tar acute or th re~t~ 
vessel closure (A&TC), and after successful recanahzatlon of a cfltontc lolal 
ecctuston (CTO). The inbavaScutar ultrasound and h~gh pressure final hal. 
Loon inflations were used in rnajonty ut cases. Clinu~l foll~e,~-up was avaLlable 
at 22 -,~ 16 menlhs 
R~sult~: 
Im:EcaPm~: ~¢¢t=ve Rest Subop! R A&TC (3'TO 
#pLs 1026 205 232 tB1 262 
Success % 99 96 9*3 93 96 
Mulup/e ste~ts 31% 2B% 36% 5;~%" 5~,b" 
Sten! p~" patient t 7 1 5 1 b 3,2" 20 
Con~ptCa~ms 5% 6% 7% t 8%" 6% 
SST 1 8% 1.7% 1.4% 1.1% t% 
Restenot~s 25% 28% ~5% 37%" 33,%" 
TLR 16% 16,% 18% 2D% 21% 
MACE 35% 31% 38% 50~ -* 38% 
• p .~ a 0t O0mp To tt,e letuP.st value; SST = sub,cute sTent hrofftbos~s 
Conclusions: The ,,se of coronary stents is safe and yields similar acute 
results with different indications, except for the A&TC The restenasis rate 
remains the major problem, in particular when stents are implanted for acute 
ar thmaterm¢l closure or following reopening a CTO. At two years MACE 
occurred tn in more than 1/3 of the patients independently of the stent 
indication. 
• R i s k  Factor Analysis for Stent Occlusion Within the First Month After Successful Coronary Stent 
Placement 
A. Sch~mig, A. Kastmti, H. ,SCh~hlen, S. Elezi, J. Hausleiter, J. DirSchinger. 
Med. Klinik & Deutsches HerzZentrum, TU MEmc#en, Germany 
Background: Technical refinements and improvements in the post-procedural 
antithmmbotic regimen have reduced the rate at st~nt occlusion (OCCL). 
Still, the rate of OCCL may vary substantially, depending on differences in 
patient and lesion characteristics, We analyzed the risk of OCCL for all 2833 
successful stenting procedures performed within the laSt 5 years, 
I00A ABSTRACTS - Poster JACC February Iggg 
MethOds: CiInl¢al, ang~ographio and procedural data were prospectively 
recorded, OCCL was verified by anglogrephy or autopsy, 
Results" The rate of OCCL was ~,3% and was associated with reajor 
cardiac events In 97%, Significant risk factors for OCCL, by Cox analy, 
sis were residual diesa¢:tlon iOR 10,2 [4,9-21,4]), overlapping stoats (OR 
1,g [1,04-3,60]) and postprocedurel therapy without ttclopldine (OR fi,2 
[2,4.,,11 ,B]), The rl.~k far OCCL, foil sharply after one week (loft graph), Title, 
pldtne was able to show Its full protootlvo effeot not before the third day after 
the procedure (fight graph), 
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Col¢luslons: The risk el OCCL depends mostly on the final result of sleet- 
Ing and poststontlng therapy, Ti~;Ioptdlno needs 2-3 days before dereostrating 
Its lull protective effeot, 
• Pmtmatment With Tl~lopldlne Reduces 
Non.Q-Wave Myooardlal  infarctions Fol lowing 
Intracomnary Slant ing 
S,R, Stoinhubt, M,S. L.eue~, D.P. Mukerjae, ~).J, Moliteme, S.G Ellis, 
E.J. Topoi, Cleveland Chn~c Founc/ation, Cleveland, OH, USA 
Background: Perl.procedural non~Q Mrs with PTCA are associated with en 
ir~craosed risk of late mortality, Aggressive antlptatolet therapy reduces the 
dsk of these events, We investigated whether pretreatm~nt with ticlopldina 
reduced the lectdence of non.Q wave Mrs followln 9 sleeting, 
Methods: The medical records of 175 patients WhO electively received o 
stoat end were pretmated with ticloptdine ware evaluated, 
Fiftdingts: 26% of these patients were treated with ticlopidine for 3 or 
mere days prior to the interventl0n, 46% for 1-2 d~,ys prior, and 2B% on the 
day el the procedure, ~llnlcal and procedural oharecteristics were similar in 
all 3 groups. Non,Q wave MI (CPK >210 IU/L) occurred significantly less 
frequently with increasing duration of therapy (Figure), 
Manta l -H~en~ze l  
Cht -~quaro  P=0,024 
w i th  CPK 
E levat ion  
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COnclusion: Tictopidine therapy pfiu, to s~enting decreases the incidence 
of non.O wave MI's ~n a dose-dependent manner, suggesting a critical rote 
for platelet inhibition in attenuating peri-procedural MI's. 
• TIGIopldln~.Asplrln as Antithrombotl¢ Regimen. 
for Intracorenary 6tenting for Unstable Angina: is 
there a Need for Further Antlplatetet Therapy? 
M, Angio~, N, Oonchln, C, Gsngloft, A, Grentzlngor, L. Jacquereln, V, Border, 
P, Houplun, Y, Jullli~re, F, Cherrier, Cardlologle, CHU Nancy, France 
Prior studios have shown significant Improvement of the results of balloon 
PT¢A In the setting of unstable angina using abcixireab. Nonafhelau in 
tllesa studies the usa of Intrecoronary Slanting was llreited, The aim of 
our study was to assess the In,h~pltal results of Intracoronsry =tenting 
with tiolopldlno,oSplrln therapy in unstable angina patients and to determine 
predlotom Of the Oocurrenco of reajor ¢~Implioatlons, 
We studied 17g oonsaoutlva patients (t44 men, moan ago 64 ~ 11 years) 
with PTGA from Novoreber 1094 to Oaceml~r tg96, without planned u~ 
of sbolxlmab, According to the Bmunwp.t~ classtfl~ation, 3?, pt~ (10%) w~m 
in 0tess I, g0 (85%) In class II and 40 (~7%) in clasP, Ill, in addition 15 pf~ 
(6%) had post myooardlal Inlarotlon unstable angina, indications for slanting 
ware', boil,out In 13 pie (7%), suboptimal results tn 1~4 pts (69%) and el~;tivO 
placement in 4~ pt~ (24%). In addition, 10 portents he~d unpl~nn~ use of 
eb¢iximob during the PTCA procedure, A reojer (;amp!italian (death, O,wav~ 
rnyocan~lial infarction, non Q,w~vo reyo~a~lial intamtion) accused tn 13 pfs 
(T,~%) alld (~llnl~l suca;0~a of th0 procedure (t~hnicpl s~oe~ of Ment 
placement without major complication) was a~hiaved in 09%, None of the 
p~tlents uncles/vent emergency GABG, Molar ~oreplcali~rl ote was 0% for 
cla~s i pts, 6,1% for aloes II Dis and t4,1% for class Ill pie (p < 0,04), On 
x,v~riate analysis, pmdiot~rs ot in,hoSpital major Coreplic~ttions were; LVEF 
(p ~-~ 0,04), steel indication (P ": O.Ot) an,:i unstable angina class (P ~ 0,06). 
Cc,nsiderlng postomy(~ardi~l nfar~tton a gina, meqor corepli~tion rate was 
5.1% in non class C pts end 2?% in class C pts (p ~ 0.01), this ditfi)ran¢;e 
remained slgnlllt;anl oven when b~ll.out procedures were excluded (p < 
0,01), 
Thus, the ree~or coreplication rate of coronap/stealing is high in class 111 
er C pts, despite the combined use of combined ticlopidine and aspinn. In 
such pts, the use of al~iximeb might be of padicular interest,. 
• Heparln DOSe Not Prevent Acute Slant 
....... :- Thrombos is  After Elective Intrecoronary Stent 
Implantat ion 
J, Suzuki, G. Hosokawa, H. Kaneda, S, Tanaka, S. Saito, 
St~onan,Karoakura General Hospital, Japan 
B~ckground: Several studies have reported that antiplatelet therapy ;ecrease 
stent throrebosts after elective sf~nt imptantatien. If coagulation activity dose 
not act as the main factor for acute stem thmmoosis, hepafin will have no 
influence on the thrombosis. 
Mefhocls: All patients were pre-traated with ticlopidine 200 mg and aspinn 
160 mg more than 2 days before the elective slant implantation. During the 
procedure we administered hepann 10,OOQ IU. After stentmg we ,~,ndomized 
to either a grasp inhibiting the hepann by protamine 100 mg or a satins 
group. We followed there for 3 days after and compared them for ACT, major 
bleeding, and cardiac events (acute steal thrombosis, death), 
Results: are summarized in the table below: 
protamtn e grotJp ._ sa!ino group P 
n 30 31 
ACT (second) 
5sin 14B ± 39 3re :L 7a ~0,001 
3hour 123 ± 20 202 • 50 40.001 
Complications 
Minor bleeding 0 4 0,O4 
Thrombosis 0 0 N~ 
Conclusion: The group using protamine did not increase acute stent 
thrombosis. Heparin dose not play the main factor for preventing acute st.. nt 
thrombosis after elective intracomnary srent implantation. 
